Actively Recruiting
Phase 2 Study of TL-925 Eye Drops for Treating Allergic Conjunctivitis Using an Allergen Challenge Model
Led by Telios Pharma, Inc. · Updated on 2024-11-13
66
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating TL-925, a topical eye drop, for the treatment of allergic conjunctivitis in a Phase 2 clinical trial. The study uses the conjunctival allergen challenge model to assess the safety and effectiveness of TL-925 compared to a placebo. Approximately 66 adult participants will be randomly assigned to one of two groups to receive either TL-925 or placebo eye drops. Participants will receive the study treatments as eye drops administered to both eyes during clinic visits. The study is double-masked and vehicle-controlled, ensuring neither participants nor researchers know who receives the active drug or placebo. The trial includes a screening period followed by treatment with the conjunctival allergen challenge model to trigger and evaluate allergic reactions. During the study, participants will be monitored closely for ocular itching and redness at several time points after allergen exposure. Researchers will assess symptoms at 3, 5, and 7 minutes for itching and at 7, 15, and 20 minutes for redness. The study focuses on evaluating the safety and effect of TL-925 on these allergic symptoms. Total participation includes screening and treatment phases under medical supervision.
CONDITIONS
Brief Title
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Research Team
J
John Mei
Y
Yulia Khalina
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here